BRCA2 and ovarian cancer: We determined the IC50 values of three standard-of-care compounds used to treat ovarian cancer in OVCAR4 cells, which are TP53-mutant but do not harbor BRCA1 or BRCA2 mutations, and observed that MPZL3 knockdown promoted resistance to cisplatin and to a lesser extent olaparib, whereas no significant difference was observed with paclitaxel treatment (Fig. 6A and B).